Literature DB >> 1815072

Mechanism of action of ginsenoside Rh2: uptake and metabolism of ginsenoside Rh2 by cultured B16 melanoma cells.

T Ota1, M Maeda, S Odashima.   

Abstract

The uptake and metabolism of ginsenoside Rh2 (Rh2) by B16 melanoma cells were studied. In a medium containing 2% fetal calf serum, the uptake of Rh2 reached a maximum of 3 nmol/10(6) cells at 3-6 h after Rh2 (12.5 microM) was added, but gradually decreased to 0.8 nmol/10(6) cells. In these cells, protopanaxadiol (PPD), which is an aglycon of Rh2, increased inversely with the decrease in Rh2 as a result of deglycosylation by the cells. When PPD (8 microM) was added to the medium, the uptake reached a plateau of 2.4 nmol/10(6) cells, within 0.5 h. The association constant of Rh2 (1.74 +/- 1.08 x 10(6) M-1) for bovine serum albumin (BSA) was significantly higher than that of PPD (9.90 +/- 1.10 x 10(4) M-1). In a serum-free medium, both Rh2 and PPD were incorporated within 1.5 h. The uptake rate constant of Rh2 (1.20 +/- 0.20 h-1) was not significantly different from that of PPD (1.02 +/- 0.15 h-1), but the release rate constant of PPD (2.12 +/- 0.38 h-1) was significantly lower than that of Rh2 (3.03 +/- 0.57 h-1). These differences in affinity for BSA and the release rate constants were thought to be the cause of the difference in uptake kinetics between these drugs. The effects of Rh2 and PPD on the cells were identical, and there was no difference in the lag periods before the appearance of their effects, despite their differing rates of uptake.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1815072     DOI: 10.1002/jps.2600801210

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  8 in total

1.  Development of a HPLC-MS assay for ginsenoside Rh2, a new anti-tumor substance from natural product and its pharacokinetic study in dogs.

Authors:  Hai-Tang Xie; Guang-Ji Wang; Hua Lv; Rui Wang Jian-Guo Sun; Xi-Ling Jiang; Hao Li; Wei Wang; Chen-Rong Huang; Mei-Juan Xu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Jan-Jun       Impact factor: 2.441

2.  Identification and characterization of the Rhizobium sp. strain GIN611 glycoside oxidoreductase resulting in the deglycosylation of ginsenosides.

Authors:  Eun-Mi Kim; Juhan Kim; Joo-Hyun Seo; Jun-Seong Park; Duck-Hee Kim; Byung-Gee Kim
Journal:  Appl Environ Microbiol       Date:  2011-10-21       Impact factor: 4.792

Review 3.  New achievements in ginseng research and its future prospects.

Authors:  Shi-feng Chu; Jun-tian Zhang
Journal:  Chin J Integr Med       Date:  2010-01-18       Impact factor: 1.978

4.  Inhibitory effects by oral administration of ginsenoside Rh2 on the growth of human ovarian cancer cells in nude mice.

Authors:  T Tode; Y Kikuchi; T Kita; J Hirata; E Imaizumi; I Nagata
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

5.  A novel drug-phospholipid complex enriched with micelles: preparation and evaluation in vitro and in vivo.

Authors:  Hai-jian Xia; Zhen-hai Zhang; Xin Jin; Qin Hu; Xiao-yun Chen; Xiao-bin Jia
Journal:  Int J Nanomedicine       Date:  2013-02-04

6.  Positive regulation of Rho GTPase activity by RhoGDIs as a result of their direct interaction with GAPs.

Authors:  Takahide Ota; Masayo Maeda; Mayumi Okamoto; Masaaki Tatsuka
Journal:  BMC Syst Biol       Date:  2015-01-28

Review 7.  Anticancer Activities of Protopanaxadiol- and Protopanaxatriol-Type Ginsenosides and Their Metabolites.

Authors:  Xiao-Jia Chen; Xiao-Jing Zhang; Yan-Mei Shui; Jian-Bo Wan; Jian-Li Gao
Journal:  Evid Based Complement Alternat Med       Date:  2016-06-30       Impact factor: 2.629

8.  Induction of apoptosis in prostate cancer by ginsenoside Rh2.

Authors:  Tony Tong-Lin Wu; Yat-Ching Tong; I-Hung Chen; Ho-Shan Niu; Yingxiao Li; Juei-Tang Cheng
Journal:  Oncotarget       Date:  2018-01-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.